These findings suggest that a single measure of NfL may not be a prognostic marker of cognitive impairment among individuals with type 2 diabetes and overweight or obesity but that serial assessments with increasing NfL levels may be a biomarker of cognitive decline in this population. This evidence concerns the gene NEFL and obesity disorder.